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Background/Aims: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are predominantly known 
as medication-induced diseases. However, at our institution, we have experienced more cases of non-drug-related SJS 
and TEN than expected. Therefore, we studied the difference between non-drug-related and drug-related SJS and 
TEN in terms of clinical characteristics and prognoses.  
Methods: The etiologies, clinical characteristics, and treatment outcomes for 82 adult patients with SJS and TEN were 
retrospectively reviewed. 
Results: A total of 71 patients (86.6%) were classified as having SJS, and the other 11 patients (13.4%) were classified 
as having TEN. Drug-related cases were more common (43, 52.4%) than non-drug-related cases (39, 47.6%). 
Anticonvulsants (12/82, 14.6%) and antibiotics (9/82, 11%) were the most common causative medications. Anemia (p 
= 0.017) and C-reactive protein of ≥ 5 mg/dL (p = 0.026) were more common in the drug-related cases than in the non-
drug-related cases. Intravenous steroid therapy was used as the main treatment regimen (70/82, 85.4%). Of the 82 
patients, 8 (9.8%) died during the clinical course. A univariate analysis for mortality showed statistical significance for 
the following: kidney function abnormality, pneumonia, hemoglobin of < 10 g/dL, and combined underlying diseases. In 
a multivariate analysis, only pneumonia was statistically significant (odds ratio, 25.79; p = 0.009).
Conclusions: Drugs were the most frequent cause of these diseases. However, non-drug-related causes also 
contributed to a significant proportion of cases. Physicians should keep this in mind when documenting patient history. 
In addition, early recognition and treatment may be important for better outcomes.
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INTRODUCTION
Stevens-Johnson syndrome (SJS) and toxic epidermal 
necrolysis (TEN) are rare but severe and potentially 
fatal mucocutaneous diseases characterized by wide-
spread epidermal necrosis and mucosal involvement 
[1,2]. At least 80% of TEN cases are believed to be drug-
induced, whereas the proportion of SJS cases attribut-
able to drugs is somewhat lower, with the estimates 
ranging between 50% and 80% [2,3]. We recently en-
countered more non-drug-related SJS and TEN cases 
than expected in our clinical practice. Several infectious 
etiologies have also been implicated in SJS and TEN. 
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the most commonly reported [4-7]. A severity-of-illness 
score for TEN, abbreviated as SCORTEN, was developed 
by Bastuji-Garin et al. [8]. In another study conducted 
in 2008, the risk of death was strongly correlated to the 
patient’s age and to the severity of the disease [9]. How-
ever, few reports on the prognostic factors of SJS and 
TEN have also included their etiologies. Therefore, in 
the present study, the etiologies, clinical characteristics, 
and treatment outcomes for a number of adult patients 
with SJS or TEN were evaluated.
METHODS
Subjects
All patients who had been consecutively admitted 
to Kyungpook National University Hospital with a di-
agnosis of SJS or TEN within the period from June 3, 
2001 to June 12, 2011, were included. The patients were 
classified as having SJS or TEN based on the diagnostic 
criteria reported by Power et al. [10]. This study was ap-
proved by the institutional review board of the authors’ 
hospital (No. KNUH-07-019).
Clinical data
Data were collected by reviewing the electronic medi-
cal database and patient charts. The medical records 
of the patients were examined to obtain the following 
data: patient demographics, presenting symptoms, 
causative drugs or events, extent of mucocutaneous 
involvement, laboratory tests, medical comorbidities, 
ocular complications, interval between symptom devel-
opment and treatment, and treatment outcome. SJS was 
characterized by an epidermal detachment of < 30% of 
the body surface area, and TEN was characterized by 
an epidermal detachment of > 30% of the body surface 
area [11]. Table 1 summarizes the definitions of the clini-
cal characteristics that were investigated.
Statistics
The variables that were expected to be related to the 
prognosis were tested via a chi-square test between the 
non-drug-related and drug-related SJS/TEN patients. 
The data were analyzed using the SPSS version 18.0 
(SPSS Inc., Chicago, IL, USA). A value of p < 0.05 was 
considered statistically significant. The prognostic fac-
tors for survival were analyzed via Fisher’s exact test 
and multivariate logistic-regression analysis with odds 
ratios (ORs) and 95% confidence intervals (CIs).
RESULTS
Demographic factors and clinical characteristics
A total of 82 consecutive patients were hospitalized 
for SJS or TEN. The demographics, presenting symp-
Table 1. Definitions of clinical characteristics that were  investigated
Clinical characteristics Definitions
Liver function abnormality Serum aspartate aminotransferase of > 40 U/L upon diagnosis    
(normal range: AST < 37 U/L, ALT < 41 U/L)
Kidney function abnormality Serum creatinine of > 2.0 mg/L upon diagnosis
Ocular complications Presence of decreased visual acuity and almost all kinds of ocular symptoms in the  
  disease course
Pneumonia Presence of a new infiltration on chest radiography or computed tomography with 
  respiratory symptoms or signs
Anemia Hemoglobin of < 10 g/dL 7 days after admission
Highest C-reactive protein and leukocyte and  
 lowest hemoglobin
These were calculated 7 days after admission
Underlying disease Diseases that patients had at the time of the diagnosis of SJS or TEN
Drug-related cases Enrolled patients who developed symptoms or signs of SJS or TEN after recent    
(< 2 wk) causative medication(s)
Non-drug-related cases Enrolled patients with no recent medication history before manifesting the symptoms 
  or signs of SJS or TEN
AST, aspartate aminotransferase; ALT, alanine aminotransferase; SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis. Kim HI, et al. Causes of Stevens-Johnson syndrome   205
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toms, and extent of mucocutaneous involvement dur-
ing the study period were reviewed. Women were more 
frequently affected than men (45, 54.9% vs. 37, 45.1%, 
respectively). The mean age at initial presentation was 
53.8 years (range, 18 to 94). The admission duration was 
2-109 days (average, 20.2). A total of 71 patients (86.6%) 
were classified as having SJS, and the other 11 patients 
(13.4%) were classified as having TEN. Mucous mem-
brane involvement was seen in the mouth (70, 85.4%), 
eye (49, 59.8%), genital area (27, 32.9%), nasal cavity (3, 
3.6%), pharynx or tonsil (2, 2.4%), and larynx (1, 1.2%). 
A total of 49 patients (59.8%) had a fever of > 38°C as 
an initial presenting symptom, and 34 patients (41.5%) 
complained of pain in the affected areas. Internal organ 
involvement comprised liver function abnormality (40, 
48.8%) and kidney function abnormality (14, 17.1%).
Laboratory tests and medical comorbidities
A total of 45 (54.9%) patients had leukocytosis (> 
10,000/mL), 49 patients (59.8%) had anemia, and 21 
patients (25.6%) had neutropenia (absolute neutrophil 
count of < 4,000/mL). The C-reactive protein (CRP) 
level was 0.2 to 42.1 mg/dL (average, 8.75), the white 
blood cell count was 3,000 to 46,460/mL (average, 
11,212), and the hemoglobin level was 3.8 to 15.1 g/dL 
(average, 11.2). Thirty-nine patients (47.6%) had un-
derlying disease, including diabetes mellitus. Twelve 
patients (14.6%) had diabetes mellitus only, and three 
patients (3.6%) had other underlying disease with 
diabetes mellitus. Other underlying diseases included 
chronic renal failure, malignancy, liver cirrhosis, gout, 
human immunodeficiency virus infection, iatrogenic 
Cushing’s syndrome, and miliary tuberculosis. One pa-
tient had multiple underlying diseases. Twelve patients 
had a medication history of anticonvulsants, and three 
patients (3.7%) had epilepsy. Cerebral hemorrhage, 
cerebral infarction, metastatic brain tumor, cerebral 
palsy, trigeminal neuralgia, hand tremor, anxiety disor-
der, headache, and back pain were each present in one 
patient, respectively. 
Causative drugs
In 43 (52.4%) of the patients with SJS or TEN, the 
disease was related to drug administration. The most 
common drugs that triggered SJS or TEN were anti-
convulsants (12/82, 14.6%), antibiotics (9/82, 11%), 
nonsteroidal anti-inflammatory drugs (NSAIDs) (5/82, 
6.1%), herbal remedies (5/82, 6.1%), allopurinol (2/82, 
2.4%), and antipsychotic drugs (1/82, 1.2%). Proton 
pump inhibitors, famciclovir, L-cysteine, and hair dye 
were among the etiologies in the patients. The most im-
portant causative drug was carbamazepine (7/82, 8.5%). 
In all patients, the administration of the causative or 
suspicious drug was discontinued after the diagnosis of 
SJS or TEN. Table 2 shows the causative drugs for the 
82 patients.
Table 2. Causes of Stevens-Johnson syndrome and 
toxic epidermal necrolysis
Cause No. (%)
Drug-related 43 (52.4)
Single drug
Anticonvulsant 12 (14.6)
Carbamazepine 7 (8.5)
Phenytoin 2 (2.4)
Valporic acid 2 (2.4)
Phenobarbital 1 (1.2)
Antibiotics 9 (11)
Cephalosporin 4 (4.9)
Penicillin 2 (2.4)
Levofloxacin 1 (1.2)
TMP-SMZ 1 (1.2)
Doxycyline 1 (1.2)
NSAID 5 (6.1)
Herb 5 (6.1)
Allopurinol 2 (2.4)
Antipsychotic 1 (1.2)
Famciclovir 1 (1.2)
L-cysteine 1 (1.2)
Hair dye 1 (1.2)
Multiple drugs
Diazepam and dantrolene sodium 1 (1.2)
Nimesulide and lansoprazole 1 (1.2)
Cefadroxil and naproxen 3 (3.7)
Hydantoin, meloxicam, and levofloxacin 1 (1.2)
Non-drug-related 39 (47.6)
TMP-SMZ, trimethoprim-sulfamethoxazole; NSAID, nonsteroidal 
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Difference between non-drug-related and drug-
induced SJS or TEN
Anemia (p = 0.017), CRP level of ≥ 5 mg/dL (p = 
0.026), and underlying disease (p = 0.001) were more 
common in the drug-related cases. Intravenous (IV) 
steroid use (p = 0.02) was more common in non-drug-
related cases. Age of > 60 years, TEN, liver function 
abnormality, kidney function abnormality, and diabetes 
mellitus were much more frequently associated with the 
drug-related cases, but this was not statistically signifi-
cant. Table 3 shows the results of the univariate analy-
sis that was conducted for the clinical characteristics 
between the drug-related and non-drug-related SJS and 
TEN cases.
Differences between patients with SJS and TEN
Skin pain (p = 0.045), underlying disease (p = 0.002), 
and diabetes mellitus (p = 0.025) were more common 
in patients with TEN. Age of > 60 years, fever of > 38℃, 
pneumonia, kidney function abnormality, septic shock, 
leukocytosis of > 15,000/mm
3, anemia, CRP of > 5 
mg/dL, drug-related cases, and death were frequent in 
patients with TEN, but did not reach statistical signifi-
cance. Table 4 shows the results of the univariate analy-
sis that was conducted to compare the clinical charac-
teristics between the SJS and TEN cases.
Treatment regimens and outcomes
Seventy patients (85.4%) were treated with IV ste-
roids, and the most common agent was dexamethasone 
(52, 63.4%). The initial steroid dose was 10 mg once 
daily. Peroral (PO) steroids in 42 patients (51.1%), along 
with prednisolone, was the most common treatment 
regimen (24, 29.3%), and the dose was 15 mg once daily. 
The interval from symptom onset to treatment with IV 
steroids was 2.21 days (range, 1 to 15), and the total pe-
riod for IV and PO steroid use was 12.68 days (range, 1 
to 68). Topical steroid ointments or lotions were used in 
67 patients (81.7%). There were no complications from 
the steroid treatment. Intravenous immunoglobulin 
(IVIG) treatment was applied in only one patient. Eight 
patients (9.8%) died, and the cause of death in four was   
SJS or TEN itself. The follow-up duration was 2-2,193 
days (average, 209.3). The results of the univariate 
analysis that was conducted to predict mortality showed 
statistical significance for the following: kidney func-
Table 3. Results of univariate analysis of the clinical characteristics of drug-related (n = 43) and non-drug-related (n 
= 39) SJS and TEN cases
Characteristics
Non-drug-related 
SJS/TEN (%)
Drug-related 
SJS/TEN (%)
p value
Age  ≥ 60 yr  16 (41) 21 (48.8) 0.478
Male 19 (48.7) 18 (41.9) 0.533
TEN   3 (7.7)   8 (18.6) 0.2
Ocular mucosa involvement 27 (69.2) 22 (51.2) 0.096
Internal organ involvement
Pneumonia   7 (17.9)   5 (11.6) 0.536
Liver function abnormality 18 (46.2) 22 (51.2) 0.650
Kidney function abnormality   4 (10.3) 10 (23.3) 0.148
Interval from drug exposure to symptoms, day       27.66
Anemia (hemoglobin < 10 g/dL) 18 (46.2) 31 (72.1) 0.017
CRP level of ≥ 5 mg/dL 18 (46.2) 29 (70.7) 0.026
Underlying disease 11 (28.2) 28 (65.1) 0.001
Diabetes mellitus   7 (17.9)   8 (18.6) 0.939
Intravenous steroid use 37 (94.9) 33 (76.7) 0.02
Steroid treatment of ≥ 7 days  32 (86.5) 22 (62.9) 0.388
Death   5 (12.8)   3 (7.0) 0.468
Death due to SJS or TEN   3 (60)   1 (33.3) 1.0
SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis; CRP, C-reactive protein.Kim HI, et al. Causes of Stevens-Johnson syndrome   207
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tion abnormality (OR, 24.75; p < 0.001), pneumonia (OR, 
34.00; p < 0.001), hemoglobin of < 10 g/dL (OR, 25.38; 
p < 0.001), and combined underlying diseases (OR, 
9.19; p = 0.017). In the multivariate logistic regression 
analysis, only pneumonia was found to be statistically 
significant as the cause of death (OR, 25.79; p = 0.009). 
The etiologies and clinical characteristics, such as age 
or sex, did not show a correlation with the prognosis. 
These results are summarized in Tables 5 and 6.
Ocular complications
Ten patients (12.2%) had ocular complications. 
The initial symptoms included ocular discharge (35, 
42.7%), decreased vision (17, 20.7%), xerophthalmia 
(20, 24.4%), ocular pain (23, 28%), and photophobia (2, 
2.4%). An ocular pseudomembrane was found in four 
patients, and corneal injury was found in two patients. 
Ocular edema and epithelial defects, superficial kera-
titis, symblepharon, and corneal infiltration were also 
found. Late ocular complications were seen in 8 patients 
(9.8%), but were not seen in 71 patients (80.7%). In nine 
patients, whether ocular complications occurred was 
unknown.
DISCUSSION
SJS and TEN are rare diseases (two cases/million 
population/year), but have significant impacts on public 
health because of their high mortality rates (20-25%) 
and complications, such as persistent corneal opacity, 
skin pigmentation, and skin scarring [2,12].
In a previous study that evaluated 207 patients with 
erythema multiforme (EM), SJS, or TEN, the most fre-
quent cause of these ailments was found to be drugs [13]. 
Another study found that only 1 (3.1%) of 32 patients 
Table 4. Comparison of univariate analysis of the clinical characteristics of SJS (n = 71) and TEN (n = 11) cases
Characteristics SJS (%) TEN (%) p value
Age ≥ 60 yr 32 (45.1) 5 (45.5) 1.0
Male 34 (47.9) 3 (27.3) 0.33
Ocular mucosa involvement 44 (62.0) 5 (45.5) 0.336
Mouth mucosa involvement 62 (87.3) 8 (72.7) 0.202
Fever of > 38ºC 42 (59.2) 7 (63.6) 0.778
Skin pain 26 (36.6) 8 (72.7) 0.024
Internal organ involvement
Pneumonia   9 (12.7) 3 (27.3) 0.199
Liver function abnormality 35 (49.3) 5 (45.5) 1.0
Kidney function abnormality 10 (14.1) 4 (36.4) 0.087
Septic shock   5 (7.0) 2 (18.2) 0.236
Leukocytes ≥ 15,000/mm
3 10 (14.1) 2 (18.2) 0.66
Anemia (hemoglobin < 10 g/dL) 18 (25.4) 5 (45.5) 0.512
C-reactive protein level of ≥ 5 mg/dL 38 (55.1) 9 (81.8) 0.094
Underlying disease 29 (40.8) 10 (90.9) 0.002
Diabetes mellitus 10 (14.1) 5 (45.5) 0.025
Intravenous steroid use 61 (85.9) 9 (81.8) 0.721
Steroid treatment duration of ≥ 7 day 48 (76.2) 6 (66.7) 0.8
Causes of disease 0.2
Drug-related 
Non-drug-related
35 (49.3)
36 (50.7)
8 (72.7)
3 (27.3)
Death   6 (8.5) 2 (18.2) 0.291
Death due to SJS or TEN   4 (66.7) 0 (0) 0.429
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with SJS or TEN was a non-drug-related case [14]. In 
the present study, drug-related cases were common (43, 
52.4%) but so were non-drug-related cases (39, 47.6%). 
All non-drug-related patients complained of various 
constitutional symptoms, such as fever, chills, myalgia, 
or sore throat, and the important and inevitable inclu-
sion criteria were the symptoms preceding the drug 
that was prescribed to reduce such symptoms or not 
having a drug history. Non-drug-related or post-upper 
respiratory tract infection-related SJS or TEN may be 
more common clinically, but patients or doctors usually 
ignore its constitutional symptoms and do not pay at-
tention to the drugs that may have caused it. To clarify 
the precise etiologies of SJS or TEN, and to prevent 
mistakes related to such, careful attention must be paid 
to patient history and medical history.
The most common triggering drugs in this study 
were anticonvulsants (carbamazepine) and antibiotics 
(cephalosporins). NSAIDs showed a lower risk in this 
study than in a previous study [2]. The so-called EuroS-
CAR study reported similar results, where the high-risk 
drugs included carbamazepine, cotrimoxazole, nevirap-
ine, phenobarbital, phenytoin, and lamotrigine, whereas 
NSAIDs showed a lower risk [15]. Jeung et al. [16] stud-
ied 11 patients with drug rash with eosinophilia and 
systemic symptoms syndrome and 20 patients with SJS. 
The most common causative agents in both diseases 
were antibiotics, followed by anticonvulsants. Anticon-
vulsants and antibiotics are traditionally the drugs that 
are highly suspected of causing SJS or TEN, along with 
NSAIDs and allopurinol. The use of such drugs as first-
line therapies should be carefully considered, especially 
when a safer alternative treatment modality exists.
In the present study, drug-related cases showed a 
frequently severe clinical course in contrast to the non-
drug-related cases, consistent with previous findings 
[17]. The non-drug-related patients represented a large 
part of the etiologies, and patient hesitation to accept 
hospital visits or to acknowledge vague symptoms may 
have contributed to the delay in early diagnosis. Physi-
cians should suspect early-phase SJS or TEN in patients 
with a short febrile history as well as sore throat and 
chills, although without a drug history.
SJS-related mortalities in previous studies have 
amounted to 0-10% of all mortalities, and TEN-related 
mortalities have amounted to 25-27% of all mortalities 
Table 6. Multivariate logistic regression analysis for the prediction of death for 82 patients with Stevens-Johnson 
syndrome or toxic epidermal necrolysis
Odds ratio 95%  confidence interval  p value
Kidney function abnormality 10.77 0.56-206.7 0.115
Pneumonia 25.79    2.25-296.21 0.009
Underlying diseases 1.86   0.11-32.26 0.669
Anemia (hemoglobin < 10 g/dL) 4.20  0.28-64.01 0.302
Table 5. Results of univariate analysis for the prediction of death for 82 patients with Stevens-Johnson syndrome 
and toxic epidermal necrolysis
Factor Odds ratio 95% confidence interval p value
Male   1.42   0.32-6.37 0.648
Age ≥ 60 yr   2.19   0.49-9.84 0.298
Extent of desquamation ≥ 30%   2.41   0.42-13.80 0.311
Eye mucosa involvement   2.16   0.41-11.44 0.355
Kidney function abnormality 24.75   4.26-143.93 < 0.001
Pneumonia 34.00   5.59-206.71 < 0.001
Anemia (hemoglobin < 10 g/dL) 25.38   2.91-221.61 < 0.001
Underlying diseases   9.19   1.05-78.49 0.017
Non-drug-related   1.96   0.44-8.81 0.373Kim HI, et al. Causes of Stevens-Johnson syndrome   209
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[10,18-22]. Optimal medical treatment for SJS and TEN 
requires early diagnosis, immediate discontinuation of 
the administration of the causative drug(s), provision 
of supportive care, and specific therapy [23]. The role of 
corticosteroids in the treatment of SJS is controversial. 
Some investigators have reported that corticosteroids 
may promote infectious complications and may lead to a 
poorer prognosis [24]. However, in recent years, steroid 
pulse therapy (e.g., with dexamethasone) in the acute 
stage of SJS/TEN has been proposed [25]. In that study, 
mortality of such patients was not higher and the time 
to re-epithelialization was not longer than expected, 
although small numbers of patients did not reach sta-
tistical significance. A small series of five patients from 
Japan suggested that early steroid pulse therapy may 
help to prevent ocular complications [26]. In the Eu-
roSCAR-study, which evaluated 281 patients with SJS/
TEN from France and Germany, mortality was chosen 
as the end point and linked to treatment with cortico-
steroids, IVIG, the combination of both, and supportive 
care only. ORs were calculated, and they suggested a 
benefit for treatment with corticosteroids but not for 
treatment with IVIG. Although such a retrospective 
analysis has some pitfalls, two major conclusions could 
be drawn: first, IVIG is not the best treatment for SJS/
TEN and cannot generally be recommended; second, a 
controlled therapeutic trial using corticosteroids should 
be undertaken [9]. IVIG, which had been reported as 
an effective treatment for TEN based on the hypothesis 
that antibodies in pooled human IVIG block the Fas-
mediated necrosis of keratinocytes in vitro, is still con-
troversial. Other studies have shown that IVIG does not 
have an overall positive effect [27]. Two further studies 
undertaken in North American burn units suggested 
that IVIG does not improve the outcome of patients 
with TEN [28,29]. In the present study, IV steroids were 
used in most of the patients, and the mortality rate 
(9.8%) was lower compared to that of previous studies. 
Further well-designed studies are required to compare 
the effects and hazards of treatment modalities for SJS 
or TEN.
The SCORTEN was developed by Bastuji-Garin et al. 
[8] and can be used to predict the mortality risk based 
on seven independent risk factors (age of ≥ 40 years, 
heart rate of ≥ 120/min, history of malignancy, total 
body surface area detached > 10%, serum urea nitrogen 
of > 10 mmol/L, serum bicarbonate of < 20 mmol/L, and 
serum glucose of > 14 mmol/L). In the present study, 
kidney function abnormality, pneumonia, low hemo-
globin (< 10 g/dL), and underlying diseases showed a 
significant negative correlation with survival in the uni-
variate analysis. Only pneumonia, however, was shown 
to be a negative prognostic factor in the multivariate 
logistic regression analysis.
Ocular involvement is common in SJS and TEN [17]. 
In a previous study, 70% of the patients manifested ocu-
lar involvement and the common signs and symptoms 
were conjunctivitis, exudates, photophobia, and cica-
trizing changes [17]. In contrast, less ocular involvement 
was found in the present study.
The limitations of this study include the fact that the 
causative agents were determined by history and did 
not depend on immunologic tests, and the treatment 
patterns differed among patients. 
SJS and TEN have traditionally been known as drug-
related systemic immune reactions. However, a defini-
tive treatment regimen among the various supportive 
therapies that have been tried has not been established. 
In this study, the etiologies and clinical characteristics 
of non-drug-related and drug-related groups were re-
viewed. Only pneumonia was found to be a statistically 
significant negative prognostic factor. The overall mor-
tality of the present study was lower than in previous 
studies, which may stem from the fact that steroid treat-
ment was a major regimen in the present study. Hence, 
our results suggest that early steroid therapy should be 
performed along with other supportive management 
measures as well as careful documentation of patient 
history for vague constitutional symptoms and upper 
respiratory tract infection.
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